Science Current Events | Science News | Brightsurf.com
 
Email a Friend Send to a friend
Printer Friendly Print M. D. Anderson study finds change in HER2 status after treatment with Herceptin

M. D. Anderson study finds change in HER2 status after treatment with Herceptin

September 04, 2008

Researchers at The University of Texas M. D. Anderson Cancer Center have discovered that when treated with Herceptin prior to surgery, 50 percent of HER2 positive, breast cancer patients showed no signs of disease at the time of surgery. However, of those women who had residual disease, about one-third had tumors that converted from HER2 positive to HER 2 negative status -possibly indicating a resistance to the targeted therapy.

The study will be presented today in advance of the American Society for Clinical Oncology Breast Cancer Symposium.




Approximately 30 percent of breast cancer cells have an excess amount of the HER2 protein on their surface, which makes the cancer more aggressive. Herceptin, also known as trastuzumab, is a monoclonal antibody that latches on to these proteins and inhibits tumor growth. It was approved in 1998 for women whose advanced, metastatic breast cancer is HER2-positive; it was approved in 2006 for use in the early setting.

It's known that a small percentage of HER2 positive patients develop a resistance to Herceptin during treatment, and there have been several described mechanisms for Herceptin resistance, said Elizabeth Mittendorf, M.D., assistant professor in M. D. Anderson's Department of Surgical Oncology.

"The goal of our study was to determine what percentage of patients who started out HER2 positive convert to HER 2 negative, suggesting that we've possibly identified another mechanism of resistance," said Mittendorf, the study's lead author. "Or we could look at it another way. Maybe the findings determine that in this subset of patients, we've treated their HER2 positive disease. Now, it's the HER2 negative disease that's able to grow."

Using the M. D. Anderson Breast Medical Oncology database, the retrospective study identified 143 early stage and locally advanced breast cancer patients, all of whom had tumors expressed HER2 at the time of diagnosis. The women were treated with Herceptin, in combination with taxane- and anthracycline-based chemotherapies, prior to surgery.

At the time of surgery, 50 percent of the women achieved a pathologic complete response (pCR), or no evidence of breast cancer. Of those who did not achieve pCR, pre- and post-treatment tissue samples were available for 23 patients The samples were analyzed using FISH, a laboratory technique that uses fluorescent probes to detect specific DNA sequences, in this case, additional copies of the HER2 gene. Seven patients, or 30.4 percent, were found to be HER2 negative at the time of surgery.

With a median follow-up of 10.2 months, the researchers also found that two patients (2.8 percent) who had achieved a pCR had recurred, compared to eight patients (11.3 percent) who did not achieve a pCR. Of the second group, tumor samples were available for five; three had converted to Herceptin negative status.

Despite these findings, at this time, the clinical applications are limited, said Mittendorf, and she strongly cautions that more research is needed before women who have a change of HER2 status not receive their scheduled Herceptin following surgery.

"At this stage, I think the findings advocate for reassessing HER2 status at the time of surgery," said Ana Gonzalez-Angulo, M.D., assistant professor in M. D. Anderson's Department of Breast Medical Oncology and the study's senior author. "However, it would be inappropriate for clinicians to conclude from our study that women with a change in HER2 status should not receive their full course of Herceptin therapy. Certainly, the study warrants further investigation of what might be the best adjuvant therapy for this sub-set of women and suggests that a clinical trial in the adjuvant setting would be appropriate."

In the lab, the researchers plan to see if there are any other changes in these tumors that are consistent with what we know about Herceptin resistance, including other mutations, alterations in specific markers. If other tumor markers of resistance are found in these patients, explains Mittendorf, then it would support the idea that HER2 status conversion promotes Herceptin resistance.

University of Texas M. D. Anderson Cancer Center



Related Herceptin Current Events and Herceptin News Articles Herceptin Current Events and Herceptin News RSS Herceptin Current Events and Herceptin News RSS
FDA approved leukemia drugs shows promise in ovarian cancer cells
The drug Sprycel, approved for use by the U.S. Food and Drug Administration in patients with chronic myeloid leukemia, significantly inhibited the growth and invasiveness of ovarian cancer cells and also promoted their death, a study by researchers with UCLA's Jonsson Comprehensive Cancer Center found.

Early-stage, HER2-positive breast cancer patients at increased risk of recurrence
Early-stage breast cancer patients with HER2 positive tumors one centimeter or smaller are at significant risk of recurrence of their disease, compared to those with early-stage disease who do not express the aggressive protein, according to a study led by researchers at The University of Texas M. D. Anderson Cancer Center.

Hunting for the Prozac Gene
Prozac works wonders for some depressed people, but not for others. In some cases, patients derive little benefit and at worst, it can lead to bizarre hallucinations and fits of rage.

Canadian cardiology team clears the way for lifesaving breast cancer treatment
A team of Canadian cardiologists, in collaboration with oncologists, are playing an important role in the war against breast cancer Dr. Michael McDonald told the Canadian Cardiovascular Congress 2009, co-hosted by the Heart and Stroke Foundation and the Canadian Cardiovascular Society.

Information about the use and accuracy of breast cancer tests is lacking, study finds
A new study finds that there is little information available about the use of new testing technologies and targeted therapies in breast cancer, specifically the anti-cancer drug trastuzumab (Herceptin).

Antibody targeting of glioblastoma shows promise in preclinical tests, say Lombardi researchers
Cancer researchers at Georgetown University's Lombardi Comprehensive Cancer Center have successfully tested a small, engineered antibody they say shuts down growth of human glioblastoma tumors in cell and animal studies. Glioblastoma is the deadliest of brain cancers; there is no effective treatment.

Triple drug combination is promising option to treat metastatic HER2+ breast cancer
Combining two chemotherapy drugs with trastuzumab (Herceptin) to treat women who have metastatic HER2+ breast cancer may offer physicians another choice in their treatment options.

Breakthrough model for human cancer may improve development of cancer drugs; study in PNAS
AVEO Pharmaceuticals, Inc., a biopharmaceutical company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today announced findings from its novel human-in-mouse (HIM) cancer model system, in which AVEO successfully created invasive human tumors from primary human breast tissue that develop over time in mice and mimic human tumor behaviors and response.

Light reveals breast tumor oxygen status
Light directed at a breast tumor through a needle can provide pathologists with biological specifics of the tumor and help oncologists choose treatment options that would be most effective for that individual patient.

Lombardi research: Monoclonal antibodies primed to become potent immune weapons against cancer
New research suggests that monoclonal antibody therapy of cancer can be improved to be much more powerful than it is today, says a researcher at Georgetown University Medical Center's Lombardi Comprehensive Cancer Center in the March 21 issue of the Lancet.
More Herceptin Current Events and Herceptin News Articles
Living Proof

Living Proof
Starring: Regina King, Swoosie Kurtz, Amy Madigan, Tom Nowicki, Bernadette Peters
Directed By: Dan Ireland

Top-rated Lifetime movie! Dr. Dennis Slamon has reached a breakthrough in his career. He has helped to develop a new experimental drug called Herceptin, which he hopes will become a revolutionary treatment in the fight against breast cancer. However, when funding for his project is cut, Slamon must turn to philanthropists Lilly Tartikoff and Ron Perelman to help make his life's most important work a reality. With the backing of his new supporters, Slamon continues to perfect his treatment, but his new drug proves that while it has the ability to give life, it does not work for everyone. This gut-wrenching true story explores one doctor's difficult struggle to find a cancer treatment that can save thousands of lives while giving meaning to his own life.

Her-2: The Making of Herceptin, a Revolutionary Treatment for Breast Cancer

Her-2: The Making of Herceptin, a Revolutionary Treatment for Breast Cancer
by Robert Bazell (Author)

Two years after she underwent a mastectomy and chemotherapy, Barbara Bradfield's aggressive breast cancer had recurred and spread to her lungs. The outlook was grim. Then she took part in Genentech's clinical trials for a new drug. Five years later she remains cancer-free.

        Her-2 is the biography of Herceptin, the drug that provoked dramatic responses in Barbara Bradfield and other women in the trials and that offers promise for hundreds of thousands of breast cancer patients. Unlike chemotherapy or radiation, Herceptin has no disabling side effects. It works by inactivating Her-2/neu--a protein that makes cancer cells grow especially quickly-- produced by a gene found in 25 to 30 percent of all breast tumors. Herceptin caused some patients' cancers to disappear...

Living Proof

Living Proof
Starring: Harry Connick Jr., Paula Cale, Angie Harmon, Bernadette Peters, Regina King
Directed By: Dan Ireland, Dan Ireland
Also With: Cathy M. Frank (Producer), Cathy M. Frank (Producer), Neil Meron (Producer), Neil Meron (Producer), Neil Meron (Producer), Neil Meron (Producer), Vivienne Radkoff (Producer), Vivienne Radkoff (Producer), Craig Zadan (Producer), Craig Zadan (Producer), Craig Zadan (Producer), Craig Zadan (Producer), Ren??e Zellweger (Producer)



  How Does Herceptin Work? A 3-D Animation
by Genentech (Author)

This is a DVD book--can be played as a standard DVD or on a computer.

Charlie Rose with Robert Bazell, Larry Norton, Fran Visco & Lois Kasper; John Edgar Wideman (September 28, 1998)

Charlie Rose with Robert Bazell, Larry Norton, Fran Visco & Lois Kasper; John Edgar Wideman (September 28, 1998)

First, Robert Bazell, author of Her 2, Dr. Larry Norton, oncologist at Memorial Sloan-Kettering Cancer Center, Lois Kasper of S.H.A.R.E, currently undergoing treatment for breast cancer with Herceptin, and Fran Visco, Chairwoman of the National Breast Cancer Coalition, sit down to talk about Herceptin as a treatment for breast cancer. Finally, John Edgar Wideman, known for his acclaimed stories of African-American life, discusses his new book, Two Cities- A Love Story, about his love of Philadelphia and Pittsburgh.

This product is manufactured on demand using DVD-R recordable media. Amazon.com's standard return policy will apply.

  Expanded use of Herceptin.(Updates): An article from: FDA Consumer
by Gale Reference Team (Author)

This digital document is an article from FDA Consumer, published by Thomson Gale on March 1, 2007. The length of the article is 454 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Expanded use of Herceptin.(Updates)
Author: Gale Reference Team
Publication: FDA Consumer (Magazine/Journal)
Date: March 1, 2007
Publisher: Thomson Gale
Volume: 41 Issue: 2 Page: 4(2)

Distributed by Thomson Gale

  Optimising the Role of Herceptin in Breast Cancer (Supplement Issue: Oncology 2001, 2)
by D. Khayat (Editor)

The humanised monoclonal antibody Herceptin[registered] targets human epidermal growth factor receptor-2 (HER2) positive cells, i.e. cells in which HER2 is overexpressed, a feature associated with many tumour characteristics. Approximately 20-30 per cent of breast cancers are HER2 positive and are known to be particularly aggressive. Thus, HER2-positive clinical trials of Herceptin[registered] have clearly demonstrated that it provides significant clinical benefit in HER2-positive metastatic dis-ease, most importantly increased survival when administered first line in combination with chemotherapy. The articles in this supplement review our knowledge of the activity of HER2 and how to test for HER2 status, and describe the clinical trials of Herceptin[registered] that have been performed...

  Herceptin: An entry from Thomson Gale's Gale Encyclopedia of Cancer, 2nd ed.
by Lee Paradise (Author)

Students, researchers, and patients can find reliable, up-to-date and clearly written information in “The Gale Encyclopedia of Cancer,” a comprehensive survey of 120 cancers, cancer drugs, traditional and alternative treatments and diagnostic procedures.



  The hype over Herceptin.(LETTERS)(Letter to the editor): An article from: Kai Tiaki: Nursing New Zealand
by Jo Fitzpatrick (Author)

This digital document is an article from Kai Tiaki: Nursing New Zealand, published by New Zealand Nurses' Organisation on March 1, 2009. The length of the article is 655 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available immediately after purchase. You can view it with any web browser.

Citation Details
Title: The hype over Herceptin.(LETTERS)(Letter to the editor)
Author: Jo Fitzpatrick
Publication: Kai Tiaki: Nursing New Zealand (Magazine/Journal)
Date: March 1, 2009
Publisher: New Zealand Nurses' Organisation
Volume: 15 Issue: 2 Page: 4(2)

Article Type: Letter to the editor

Distributed by Gale, a part of Cengage...

  Early Herceptin use cuts breast Ca recurrence in half: 'stunning' results when used as adjuvant tx.(News): An article from: OB GYN News
by Jane Salodof MacNeil (Author)

This digital document is an article from OB GYN News, published by Thomson Gale on June 15, 2005. The length of the article is 932 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Early Herceptin use cuts breast Ca recurrence in half: 'stunning' results when used as adjuvant tx.(News)
Author: Jane Salodof MacNeil
Publication: OB GYN News (Magazine/Journal)
Date: June 15, 2005
Publisher: Thomson Gale
Volume: 40 Issue: 12 Page: 1(2)

Distributed by Thomson...

© 2009 BrightSurf.com